Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
Open Access
- 31 July 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (15), 4987-4995
- https://doi.org/10.1158/1078-0432.ccr-11-0207
Abstract
Purpose: We investigated the antitumor reactivity of adoptively transferred effector B cells and the mechanisms by which they may mediate tumor regression in a spontaneous metastases model. Experimental Design: 4T1 breast cancer cells were inoculated into the flanks of syngeneic Balb/C mice to prime draining lymph nodes. Tumor-draining lymph nodes (TDLN) were harvested and B cells activated ex vivo with lipopolysaccharide and anti-CD40 monoclonal antibody. These activated B cells were adoptively transferred into mice inoculated with 4T1 tumor in the mammary fat pad. The induction of host T-cell immunity was evaluated. Results: Activated 4T1 TDLN B cells secreted immunoglobulin G (IgG) in response to tumor cells which was immunologically specific. These activated B cells were capable of mediating specific lysis of tumor cells in vitro. Transfer of these activated B cells alone mediated the inhibition of spontaneous metastases to the lung. Examination of the host revealed that the transfer of these B cells resulted in the induction of tumor-specific T-cell immunity as measured by cytotoxicity and cytokine (IFNγ and granulocyte-macrophage colony-stimulating factor) production. The combined transfer of activated T and B cells from TDLN resulted in tumor regression, which was greater than either cell population alone, with host B cells capable of producing IgG that mediated lysis of tumor in the presence of complement. Conclusions: We have found that appropriately primed B cells can mediate tumor regression by itself and confers host T-cell antitumor immunity. Furthermore, effector B cells can serve as a useful adjunct in adoptive T-cell therapy. Clin Cancer Res; 17(15); 4987–95. ©2011 AACR.Keywords
This publication has 35 references indexed in Scilit:
- CD20+ B Cells: The Other Tumor-Infiltrating LymphocytesThe Journal of Immunology, 2010
- B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in MiceThe Journal of Immunology, 2010
- CD137 Promotes Proliferation and Survival of Human B CellsThe Journal of Immunology, 2009
- Cutting Edge: Importance of IL-6 and Cooperation between Innate and Adaptive Immune Receptors in Cellular Vaccination with B LymphocytesThe Journal of Immunology, 2009
- In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive ImmunotherapyThe Journal of Immunology, 2009
- Antigen Receptor Signals Rescue B Cells from TLR ToleranceThe Journal of Immunology, 2009
- Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral ResponsesCancer Research, 2008
- Resting B Cells Suppress Tumor Immunity via an MHC Class-II Dependent MechanismJournal of Immunotherapy, 2007
- Inhibitory Effects of B Cells on Antitumor ImmunityCancer Research, 2006
- Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti-tumor CTL and TH1 cytokine responses by B cellsInternational Journal of Cancer, 2005